Surf: Open label, randomized multi-centre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma (mRCC)
ANNALS OF ONCOLOGY（2016）
关键词
Renal cell carcinoma,Sunitinib,Metastatic,Schedule,Toxicity,Safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要